Gujarat Inject (Kerala) Limited auditor flags Rs 5.74 crore receivable

Gujarat Inject (Kerala) Limited's auditor identified Rs 5.74 crore of current trade receivables outstanding for more than one year without an expected credit loss provision in the review for the half year ended September 30, 2026. Management said reported amounts were unaffected because it sees a possibility of recovery, while acknowledging a future provision or write-off may be required.

What did Gujarat Inject's auditor flag in the September 2026 review?

Gujarat Inject's auditor flagged Rs 5.74 crore of current trade receivables that had been outstanding for more than one year as of September 30, 2026, with no expected credit loss, or ECL, provision recorded. The observation appeared in the independent auditor's review report dated November 5, 2026, covering the quarter ended September 30, 2026 and the six-month period from April 1, 2026 to September 30, 2026.

The filing does not identify the counterparty or counterparties behind the Rs 5.74 crore balance, disclose when the dues first fell due, or provide a collection timetable. It records only that the receivable had crossed the one-year ageing threshold and that no ECL provision had been made. The reported receivable and profit figures for September 30, 2026 therefore remained unadjusted for this matter.

The auditor conducted a limited review under Standard on Review Engagements 2410, rather than a full audit. The report states that a review provides moderate assurance and is substantially less extensive than an audit. Its conclusion says that, except for the effects of the ECL non-provision, the conclusion was not modified.

How does Gujarat Inject assess the Rs 5.74 crore receivable?

Gujarat Inject said management believes there is a possibility of recovering the Rs 5.74 crore and therefore sees no effect on reported financial-statement amounts for the half year ended September 30, 2026. The company made this statement in its impact-of-audit-qualifications disclosure dated November 5, 2026, where the matter was described as first-time reporting.

Management also specified the condition that could alter that assessment. If any part, or all, of the outstanding dues becomes non-recoverable, Gujarat Inject said it may have to write off the amount or create a doubtful-debt provision or ECL to that extent when such an event occurs. The filing does not estimate a possible charge between nil and the full Rs 5.74 crore.

The impact statement showed no adjustment to the reported figures for the ECL matter. Total income was listed at Rs 18.27 crore, total expenditure at Rs 16.30 crore, net profit at Rs 1.98 crore, total assets at Rs 28.99 crore and net worth at Rs 13.39 crore both before and after adjustment. Earnings per share were shown at Rs 0.13 in both columns.

What other balance did Gujarat Inject's auditor mention?

Gujarat Inject's auditor separately noted Rs 4.31 crore of loans and advances within non-current financial assets for which the company had not received contra confirmations by November 5, 2026. A contra confirmation is confirmation of a recorded balance by the other party. The report treated this observation separately from the aged trade receivable and ECL issue.

The two observations concern different balance-sheet categories and mechanisms. The Rs 5.74 crore amount is a current trade receivable outstanding beyond one year without an ECL provision, while the Rs 4.31 crore balance consists of non-current loans and advances without contra confirmations. The filing does not say that the Rs 4.31 crore amount is overdue or that an ECL provision is required for it.

The review report also drew attention to a proposed preferential issue of equity share warrants after an increase in authorised capital, and to the capitalisation of a solar power generation project from capital work in progress into property, plant and equipment. It said revenue recognition from the solar project had commenced, but did not disclose the solar project's revenue for the half year ended September 30, 2026.

What do Gujarat Inject's half-year figures show alongside the receivable issue?

Gujarat Inject reported profit before tax of Rs 2.64 crore in its standalone cash-flow statement for the half year ended September 30, 2026, compared with Rs 18.82 lakh in the corresponding half year ended September 30, 2025. This increase in the reported profit measure coincided with operating cash moving to an outflow of Rs 57.92 lakh in the 2026 half year, from an inflow of Rs 19.09 lakh a year earlier.

The cash-flow statement records working-capital movements during the September 2026 half year, including Rs 1.34 crore for inventories, Rs 1.81 lakh for trade receivables and Rs 3.03 crore for trade payables. It does not separately identify whether the Rs 5.74 crore aged receivable noted by the auditor caused the reported trade-receivables movement. The cash-flow statement was prepared using the indirect method under Indian Accounting Standard 7.

Net cash used in operating activities was Rs 58.28 lakh in the half year ended September 30, 2026, compared with net cash from operating activities of Rs 19.09 lakh in the corresponding 2025 period. Investing activities used Rs 4.74 lakh in the 2026 half year, compared with Rs 5.74 lakh of net cash from investing activities in the prior-year period. These cash-flow movements are separate from management's Rs 5.74 crore recoverability assessment.

Conclusion

The November 5, 2026 review places Rs 5.74 crore of trade receivables outstanding beyond one year at the centre of Gujarat Inject's disclosure because no ECL provision has been recorded. Management's assessment that recovery remains possible left the September 30, 2026 figures unchanged, including net profit of Rs 1.98 crore, even as operating activities used Rs 58.28 lakh of cash in the half year.

The next disclosed matter to watch is whether Gujarat Inject collects the Rs 5.74 crore overdue balance or records a write-off, doubtful-debt provision or ECL if recoverability changes. The company has also disclosed a proposed preferential warrant issue, commencement of revenue recognition from its solar project, and Rs 4.31 crore of non-current loans and advances awaiting contra confirmations as of November 5, 2026.